Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...
GlobalData predicts that Lilly’s retatrutide could reach sales of $15.6bn in 2031. Image credit: Jennie Book / Shutterstock.com. Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight ...
Dyne Therapeutics reported six-month and 24-month data from the Phase I/II trial. Image credit: Sheldon Cooper / SOPA Images / LightRocket via Getty Images. Dyne Therapeutics is seeking US accelerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback